Δευτέρα 3 Απριλίου 2017

AACR 2017: Biomarker may identify neuroblastoma patients most likely to benefit from immunotherapy

Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nzQO67
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις